Alcohol addiction - the safety of available approved treatment options

References

• Maher JJ. Alcoholic liver disease. In: Feldman M, Friedman LS, Sleisenger MH, editors. Gastrointestinal and Liver Disease. Philadelphia (PA): Saunders. 2002 May-Apr. p. 1375–1391.
   Google Scholar
• Verheul R, Van Den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999;34(2):197–222.
   PubMed Web of Science ®Google Scholar
• The ESPAD Group. ESPAD Report 2015. Results from the European school survey project on alcohol and other drugs. Lisbon: European Monitoring Centre on Drugs and Drug Addiction; 2016.
   Google Scholar
• Addolorato G, Leggio L, Abenavoli L, et al. Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav. 2005;30:1209–1224.
   PubMed Web of Science ®Google Scholar
• Vaccari A, Saba PL, Ruiu S, et al. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol. 1996;139:102–108.
   PubMed Web of Science ®Google Scholar
• Heinz A, Siessmeier T, Wrase J, et al. Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry. 2004;161:1783–1789.
   PubMed Web of Science ®Google Scholar
• Frascella J, Potenza MN, Brown LL, et al. Shared brain vulnerabilities open the way for nonsubstance addictions: craving addiction at a new joint? Ann NY Acad Sci. 2010;1187:294–315.
   PubMed Web of Science ®Google Scholar
• Mutschler J, Grosshans M, Soyka M, et al. Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry. 2016 Jul;49(4):137–141.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992 Nov;49(11):881–887.
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Daeppen JB. Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. Drug Alcohol Depend. 2013;133:15–29.
   PubMed Web of Science ®Google Scholar
• Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77(2):315–323.
   PubMed Web of Science ®Google Scholar
• Oka M, Hirouchi M, Tamura M, et al. Acamprosate monocalcium bis(3-acetamidopropane-1-sulfonate) reduces ethanol-drinking behavior in rats and glutamate-induced toxicity in ethanol-exposed primary rat cortical neuronal cultures. Eur J Pharmacol. 2013;718(1–2–3):323–331.
   PubMed Web of Science ®Google Scholar
• Plosker GL. Acamprosate: a review of its use in alcohol dependence. DRUGS. 2015 Jul;75(11):1255–1268.
   Google Scholar
• Mann K, Kiefer F, Spanagel R, et al. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res. 2008;32(7):1105–1110.
   PubMed Web of Science ®Google Scholar
• Umhau JC, Momenan R, Schwandt ML, et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry. 2010;67(10):1069–1077.
   PubMedGoogle Scholar
• Maccioni P, Carai MA, Kaupmann K, et al. Reduction of alcohol’s reinforcing and motivational properties by the positive allosteric modulator of the GABA(B) receptor, BHF177, in alcohol-preferring rats. Alcohol Clin Exp Res. 2009;33:1749–1756.
   PubMed Web of Science ®Google Scholar
• Gessa GL, Crabai F, Yargiu L, et al. Selective increase of brain dopamine induced by gamma-hydroxybutyrate: study of the mechanism of action. J Neurochem. 1968;15(5):377–381.
   PubMed Web of Science ®Google Scholar
• Poldrugo F, Addolorato G. The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol. 1999 Jan-Feb;34(1):15–24.
   PubMed Web of Science ®Google Scholar
• Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med. 2005 Jun 30;352(26):2721–2732.
   PubMed Web of Science ®Google Scholar
• Duke AN, Kaminski BJ, Weerts EM. Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons. Addict Biol. 2014;19:16–26.
   PubMed Web of Science ®Google Scholar
• Leggio L, Ferrulli A, Zambon A, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37:561–564.
   PubMed Web of Science ®Google Scholar
• Chick J, Nutt DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol. 2012 Feb;26(2):205–212.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des. 2010;16(19):2113–2117.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Agabio R, et al. Baclofen: a new drug for the treatment of alcohol dependence. Int J Clin Pract. 2006 Aug;60(8):1003–1008.
   PubMed Web of Science ®Google Scholar
• Müller CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015 Aug;25(8):1167–1177.
   PubMed Web of Science ®Google Scholar
• Reynaud M, Aubin HJ, Trinquet F, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol. 2017 Jul 1;52(4):439–446.
   PubMed Web of Science ®Google Scholar
• Beraha EM, Salemink E, Goudriaan AE, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol. 2016 Dec;26(12):1950–1959.
   PubMed Web of Science ®Google Scholar
• Morley KC, Logge W, Pearson SA, et al. National trends in alcohol pharmacotherapy: findings from an Australian claims database. Drug Alcohol Depend. 2016;166:254–257.
   PubMed Web of Science ®Google Scholar
• Goh ET, Morgan MY. Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Aliment Pharmacol Ther. 2017 Apr;45(7):865–882.
   PubMed Web of Science ®Google Scholar
• Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017 Feb;130(2):124–134.
   PubMed Web of Science ®Google Scholar
• Berlin RG. Disulfiram hepatotoxicity: a consideration of its mechanism and clinical spectrum. Alcohol Alcoholism. 1989;24:241–246.
   PubMed Web of Science ®Google Scholar
• Forns X, Caballería J, Bruguera M, et al. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol. 1994 Nov;21(5):853–857.
   PubMed Web of Science ®Google Scholar
• Eneanya DI, Bianchine JR, Duran DO, et al. The actions of metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol. 1981;21:575–596.
   PubMed Web of Science ®Google Scholar
• Chick J. Disulfiram: cautions on liver function; how to supervise. Addiction. 2004 Jan;99(1):25. author reply 27–28.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol. 2006;44:791–797.
   PubMed Web of Science ®Google Scholar
• Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse. 2006;41:1395–1463.
   PubMed Web of Science ®Google Scholar
• Eliasson E, Stål P, Oksanen A, et al. Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis. J Hepatol. 1998;29:819–825.
   PubMed Web of Science ®Google Scholar
• Ju C. Immunological mechansisms of drug-induced liver injury. Curr Opin Drug Discov Develop. 2005;8:38–43.
   PubMedGoogle Scholar
• Addolorato G, Mirijello A, Barrio P, et al. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016;65(3):618–630.
   PubMed Web of Science ®Google Scholar
• Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 2010;16:2091–2097.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34:1849–1857.
   PubMed Web of Science ®Google Scholar
• Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res. 2012;36:318–324.
   PubMed Web of Science ®Google Scholar
• Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs. 2012 Nov;73(6):991–997.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jama. 2014;311(18):1889–1900.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf. 2010;9:177–188.
   PubMed Web of Science ®Google Scholar
• Delgrange T, Khater J, Capron D, et al. Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis. Gastroenterol Clin Biol. 1992;16:687–691.
   PubMedGoogle Scholar
• Caputo F, Bernardi M, Zoli G. Efficacy and safety of c-hydroxybutyrate in treating alcohol withdrawal syndrome in an alcohol-dependent inpatient with decompensated liver cirrhosis: a case report. J Clin Psychopharmacol. 2011;31:140–141.
   PubMed Web of Science ®Google Scholar
• Caputo F, Vignoli T, Tarli C, et al. A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder. Int J Environ Res Public Health. 2016 Mar 5;13(3):pii: E290.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–1922.
   PubMed Web of Science ®Google Scholar
• Heydtmann M. Baclofen effect related to liver damage. Alcohol Clin Exp Res. 2011;35(5):848.
   PubMed Web of Science ®Google Scholar
• Yamini D, Lee SH, Avanesyan A, et al. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol. 2014;49(4):453–456.
   PubMed Web of Science ®Google Scholar
• Owens L, Rose A, Thompson A, et al. Baclofen: maintenance of abstinence in alcohol dependent patients attending liver clinic. J Hepatol. 2015;62:S767.
   Web of Science ®Google Scholar
• Hauser P, Fuller B, Ho SB, et al. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction. 2017 Jul;112(7):1173–1183.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010 Nov;34(11):1849–1857.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jama. 2014 May 14;311(18):1889–1900.
   PubMed Web of Science ®Google Scholar
• Barrault C, Lison H, Roudot-Thoraval F, et al. One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. Eur J Gastroenterol Hepatol. 2017 Oct;29(10):1155–1160.
   PubMed Web of Science ®Google Scholar
• Owens L, Thompson A, Rose A, et al. A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. Alcohol. 2017;62:11–15.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57(2):399–420.
   PubMed Web of Science ®Google Scholar
• Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis. Hepatology. 2013;57:1651–1653.
   PubMed Web of Science ®Google Scholar
• Swift R. Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm. 2007 Mar 1;64(5 Suppl 3):S12–22.
   PubMedGoogle Scholar
• Bilsel Y, Bugra D, Yamaner S, et al. Could honey have a place in colitis therapy? Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation. Dig Surg. 2002;19(4):306–311.
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005 Jun;8(2):267–280.
   PubMed Web of Science ®Google Scholar
• Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11.
   PubMed Web of Science ®Google Scholar
• Verma R. Naltrexone-associated acute pancreatitis. Prim Care Companion CNS Disord. 2016 Nov 24;18(6).
   PubMedGoogle Scholar
• Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 2002;67(1):89–94.
   PubMed Web of Science ®Google Scholar
• Skala K, Caputo F, Mirijello A, et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother. 2014;15:245–257.
   PubMed Web of Science ®Google Scholar
• Busardò FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13:47–70.
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Ang D, Pauwels A, et al. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016 May;13(5):281–294.
   PubMed Web of Science ®Google Scholar
• Pike MG, Mays DC, Macomber DW, et al. Metabolism of a disulfiram metabolite, S-methyl N,N-diethyldithiocarbamate, by flavin monooxygenase in human renal microsomes. Drug Metab Dispos. 2001;29:127–132.
   PubMed Web of Science ®Google Scholar
• Williams SH. Medications for treating alcohol dependence. Am Fam Physician. 2005 Nov 1;72(9):1775–1780.
   PubMed Web of Science ®Google Scholar
• Ac K, Volpicelli JR, Gunduz M, et al. Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res. 1997 Aug;21(5):906–909.
   PubMed Web of Science ®Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Jama. 2006 May 3;295(17):2003–2017.
   PubMed Web of Science ®Google Scholar
• Jaiswal D, Uzans D, Hayden J, et al. Targeting the opioid pathway for uremic pruritus: a systematic review and meta-analysis. Can J Kidney Health Dis. 2016 Dec;13(3):2054358116675345.
   Google Scholar
• Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013 Nov;23(11):1432–1442.
   PubMed Web of Science ®Google Scholar
• Overman GP, Teter CJ, Guthrie SK. Acamprosate for the adjunctive treatment of alcohol dependence. Ann Pharmacother. 2003;37(7–8):1090–1099.
   PubMed Web of Science ®Google Scholar
• Haller C, Thai D, Jacob P 3rd, et al. GHB urine concentrations after single-dose administration in humans. J Anal Toxicol. 2006 Jul-Aug;30(6):360–364.
   PubMed Web of Science ®Google Scholar
• Moldofsky H, Inhaber NH, Guinta DR, et al. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol. 2010 Oct;37(10):2156–2166.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46(3):312–317.
   PubMed Web of Science ®Google Scholar
• Chen KS, Bullard MJ, Chien YY, et al. Baclofen toxicity in patients with severely impaired renal function. Ann Pharmacother. 1997 Nov;31(11):1315–1320.
   PubMed Web of Science ®Google Scholar
• Roberts JK, Westphal S, Sparks MA. Iatrogenic baclofen neurotoxicity in ESRD: recognition and management. Semin Dial. 2015 Sep-Oct;28(5):525–529.
   PubMed Web of Science ®Google Scholar
• Porter LM, Merrick SS, Katz KD. Baclofen toxicity in a patient with hemodialysis-dependent end-stage renal disease. J Emerg Med. 2017 Apr;52(4):e99–e100.
   PubMed Web of Science ®Google Scholar
• Enghusen Poulsen H, Loft S, Andersen JR, et al. Disulfiram therapy: adversedrug reactions and interactions. Acta Psychiatr Scand Suppl. 1992;369:59–65.
   PubMedGoogle Scholar
• Thu Tran A, Rison RA, Beydoun SR. Disulfiram neuropathy: two case reports. J Med Case Rep. 2016;10:72.
   PubMedGoogle Scholar
• Frisoni GB, Di Monda V. Disulfiram neuropathy: a review (1971–1988) and report of a case. Alcohol Alcohol. 1989;24(5):429–437.
   PubMed Web of Science ®Google Scholar
• Karamanakos PN, Pappas P, Stephanou P, et al. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism. Pharmacol Toxicol. 2001 Feb;88(2):106–110.
   PubMedGoogle Scholar
• Larson EW, Olincy A, Rummans TA, et al. Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcohol Clin Exp Res. 1992;16:125–130.
   PubMed Web of Science ®Google Scholar
• Tartara E, Fanucchi S, D’Errico I, et al. A case of Wernicke encephalopathy combined with disulfiram intoxication. Cogn Behav Neurol. 2013;26(2):93–98.
   PubMed Web of Science ®Google Scholar
• Croop RS, Faulkner EB, Labriola DF. The Naltrexone Usage Study Group. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. Arch Gen Psychiatry. 1997;54:1130–1135.
   PubMed Web of Science ®Google Scholar
• Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010;9:13–22.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Bifulco F, Cuomo A, et al. The challenge of perioperative pain management in opioid-tolerant patients. Ther Clin Risk Manag. 2017 Sep;5(13):1163–1173.
   Google Scholar
• Dunbar JL, Turncliff RZ, Dong Q, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30(3):480–490.
   PubMed Web of Science ®Google Scholar
• Franchitto N, Jullian B, Salles J, et al. Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians. Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):669–677.
   PubMed Web of Science ®Google Scholar
• Engelhard K, Werner C, Lu H, et al. The neuroprotective effect of the glutamate antagonist acamprosate following experimental cerebral ischemia. A study with the lipid peroxidase inhibitor u-101033e. Anaesthesist. 2000;49:816–821.
   PubMedGoogle Scholar
• Al Qatari M, Khan S, Harris B, et al. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res. 2001 Sep;25(9):1276–1283.
   PubMed Web of Science ®Google Scholar
• Kim SI, Barker JC, Anderson BI, et al. Systematic Assessment of Gamma Hydroxybutyrate (GHB) effects during and after acute intoxication. Am J Addict. Am J Addict. 2008 Jul–Aug;17(4):312–318.
   PubMed Web of Science ®Google Scholar
• MüLler CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25:1167–1177.
   PubMed Web of Science ®Google Scholar
• Rigal L, Alexandre-Dubroeucq C, De Beaurepaire R, et al. Abstinence and ‘low risk’ consumption 1 year after the initiation of high-dose baclofen: a retrospective study among ‘high-risk’ drinkers. Alcohol Alcohol. 2012;47:439–442.
   PubMed Web of Science ®Google Scholar
• Leung NY, Whyte IM, Isbister GK. Baclofen overdose: defining the spectrum of toxicity. Emerg Med Australas. 2006;18(1):77–82.
   PubMedGoogle Scholar
• Rolland B, Auffret M, Franchitto N. Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment. Expert Opin Drug Saf. 2016 Jun;15(6):747–751.
   PubMed Web of Science ®Google Scholar
• Rolland B, Jaillette E, Carton L, et al. Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. J Clin Psychopharmacol. 2014 Feb;34(1):153–156.
   PubMed Web of Science ®Google Scholar
• Gallimberti L, Ferri M, Ferrara SD, et al. γ-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res. 1992;16:673–676.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Castelli E, Stefanini GF, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol Alcohol. 1996;31:341–345.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Cibin M, Capristo E, et al. Maintaining abstinence from alcohol by gamma-hydroxybutyric acid. Lancet. 1998;351:38.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs. 2009;18(5):1–12.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Caputo F, Capristo E, et al. Gamma-hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol. 2000;20:217–222.
   PubMed Web of Science ®Google Scholar
• Rosenberg MH, Deerfield LJ, Baruch EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse. 2003;29(2):487–496.
   PubMed Web of Science ®Google Scholar
• Caputo F, Vignoli T, Grignaschi A, et al. Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. Eur Neuropsychopharmacol. 2014 Feb;24(2):181–191.
   PubMed Web of Science ®Google Scholar
• DeVido J, Bogunovic O, Weiss RD. Alcohol use disorders in pregnancy. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):112–121.
   PubMed Web of Science ®Google Scholar
• Rolland B, Paille F, Gillet C, et al. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 2016 Jan;22(1):25–37.
   PubMed Web of Science ®Google Scholar
• McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994;8(6):461‐475.
   PubMed Web of Science ®Google Scholar
• Wikner BN, Stiller C-O, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(11):1203‐1210.
   Web of Science ®Google Scholar
• Nora H, Nora J, Blu J. Limb reduction anomalies in infants born to disulfiram-treated alcohol mothers. Lancet. 1977;3:664–669.
   Google Scholar
• Helmbrecht GD, Hoskins IA. First trimester disulfiram exposure: report of two cases. Am J Perinatol. 1993;10(1):5–7.
   PubMed Web of Science ®Google Scholar
• Zagon IS, Tobias SW, Hytrek SD, et al. Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters mu opioid receptors. Pharmacol Biochem Behav. 1998;59:201–207.
   PubMed Web of Science ®Google Scholar
• Product monograph, Campral Acamprosate calcium, delayed release tablets 333mg, alcohol abstinence aid; Mylan pharmaceuticals ULC. 2011 Sep 8.
   Google Scholar
• Barker EC, Puchowicz M, Letterio J, et al. GHB levels in breast milk of women with narcolepsy with cataplexy treated with sodium oxybate. Sleep Med. 2017;36:172–177.
   PubMed Web of Science ®Google Scholar
• Ratnayaka BDM, Dhaliwal H, Watkin S. Drug points: neonatal convulsions after withdrawal of baclofen. Bmj. 2001;323(7304):85.
   PubMedGoogle Scholar
• Takacs R, Milan F, Ungvari GS, et al. Catatonia in disulfiram intoxication- a casereport and a brief overview of the literature. Neuropsychopharmacologia Hungarica. 2016 Jun;18(2):110–114.
   PubMedGoogle Scholar
• Olivier PY, Joyeux-Faure M, Gentina T, et al. Severe central sleep apnea associated with chronic baclofen therapy: a case series. Chest. 2016 May;149(5):e127–131.
   PubMed Web of Science ®Google Scholar
• Pelissier F, De Haro L, Cardona F, et al. Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008–2013. Clin Toxicol (Phila). 2017;55(4):275–284.
   PubMed Web of Science ®Google Scholar
• Preuss UW, Gouzoulis-Mayfrank E, Havemann-Reinecke U, et al. Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines. Eur Arch Psychiatry Clin Neurosci. 2017 Apr 24.
   PubMed Web of Science ®Google Scholar
• Haass-Koffler CL, Goodyear K, Zywiak W, et al. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend. 2017 Aug 1;177:23–28.
   PubMed Web of Science ®Google Scholar
• Winslow BT, Onysko M, Hebert M. Medications for alcohol use disorder. Am Fam Physician. 2016 Mar 15;93(6):457–465.
   PubMed Web of Science ®Google Scholar